Advancing Myeloma Care: Innovative CAR-T Updates
Join renowned myeloma expert Dr. Natalie Callander for an in-depth and timely webinar, Advancing Myeloma Care: The Next Wave of CAR-T Innovation, focused exclusively on the rapidly evolving landscape of CAR-T therapy for multiple myeloma. Dr. Callander will explore next-generation CAR-T treatments currently under investigation and the emerging science of in vivo CAR-T, explaining what makes these approaches different and how they may expand access and improve outcomes. Designed specifically for patients and caregivers, this session will provide clear, practical insights into where CAR-T therapy stands today, what these innovations could mean for your care, and what may be coming next.
Cindy introduces the agenda of the event and featured speaker Dr. Natalie Callander
Dr. Callander talks about CAR- T therapy for myeloma
Type your questions in the chat and we will answer them!
Cynthia Cahoon, RN
Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.
Natalie Callander, MD
Dr. Natalie Callander is a faculty member in Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine. She is the Director of the UW Carbone Cancer Center Myeloma Clinical Program, Vice Chair of the NCCN Myeloma Committee, and Interim Director of Bone Marrow Transplant. She is a member of the NCI Myeloma Steering Committee and the ECOG Myeloma Committee She has received three UW Health Patient Experience Physician Champion Awards, named to Best Doctors in America list since 2004, a Madison Magazine Top Doctor three times, and received the Chuck Koval Award for Excellence in Myeloma presented by the Leukemia and Lymphoma Society.